Comparison of different absorption enhancers on the intranasal absorption of isosorbide dinitrate in rats

International Journal of Pharmaceutics

Volumn 397, Issue 1-2, 2010, Pages 59-66

  Na, Lidong ^a   Mao, Shirui ^a   Wang, Juan ^a   Sun, Wei ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Absorption enhancers; In situ nasal perfusion; In vivo pharmacokinetics; Intranasal; Isosorbide dinitrate

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CHITOSAN; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; PARACETAMOL; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUTION; FEMALE; IN VIVO STUDY; MALE; NASAL CILIOTOXICITY; NONHUMAN; NOSE DISEASE; PH MEASUREMENT; PRIORITY JOURNAL; RAT;

ABSORPTION; ADMINISTRATION, INTRANASAL; ANIMALS; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; HYDROGEN-ION CONCENTRATION; ISOSORBIDE DINITRATE; MALE; NASAL MUCOSA; POLOXAMER; RATS; RATS, WISTAR; VASODILATOR AGENTS;

EID: 77955984673     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.06.048     Document Type: Article

References (37)

1. All S.L., Blume H. Determination of isosorbide dinitrate and its two mononitrate metabolites in human plasma and saliva through gas-liquid chromatography with electron-capture detection. Fresenius' J. Anal. Chem. 1985, 321:257-262.
2. Asai K., Morishita M., Katsuta H., Hosoda S., Shinomiya K., Noro M., Nagai T., Takayama K. The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa. Int. J. Pharm. 2002, 246:25-35.
3. Aspden T.J., Illum L., Skaugrud Ø. Chitosan as a nasal delivery system: evaluation of insulin absorption enhancement and effect on nasal membrane integrity using rat models. Eur. J. Pharm. Sci. 1996, 4:23-31.
4. Behl C.R., Pimplaskar H.K., Sileno A.P., deMeireles J.C., Romeo V.D. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Deliv. Rev. 1998, 29:89-116.
5. Boonyo W., Junginger H.E., Waranuch N., Polnok A., Pitaksuteepong T. Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration. J. Control Release 2007, 121:168-175.
6. Borchard G., Lueßen H.L., De Boer G.A., Coos Verhoef J., Lehr C.M., Junginger H.E. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III. Effects of chitosan glutamate and carbomer on epithelial tight junctions in vitro. J. Control Release 1996, 39:131-138.
7. Chandler S.G., Thomas N.W., Ilium L. Nasal absorption in the rat. IV. Membrane activity of absorption enhancer. Int. J. Pharm. 1995, 117:139-146.
8. Chavanpatill M.D., Vavia P.R. The influence of absorption enhancers on nasal absorption of acyclovir. Eur. J. Pharm. Biopharm. 2004, 57:483.
9. Cjoappetta D.A., Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability. Eur. J. Pharm. Biopharm. 2007, 66:303-317.
10. Deli M.A. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim. Biophys. Acta 2009, 1788:892-910.
11. Gould S., Scott R.C. 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review. Food Chem. Toxicol. 2005, 43:1451-1459.
12. Gu F.G., Cui F.D., Gao Y.D. Preparation of prostaglandin E1-hydroxypropyl-γ-cyclodextrincomplex and its nasal delivery in rats. Int. J. Pharm. 2005, 290:101-108.
13. Hirai S., Yashiki T., Matsuzawa T., Mima H. Absorption of drugs from the nasal mucosa. Int. J. Pharm. 1981, 7:317-325.
14. Hussain M.A., Mersinger L., Maurin M.B., Kettner C. In situ characterization of nasal leucine enkephalin degrading aminopeptidase. Susceptibility of the nasal enzyme to boronic acids and phosphorus-containing peptide and amino acid isosteres. Int. J. Pharm. 1995, 117:181-188.
15. Hussain A.A. Intranasal drug delivery. Adv. Drug Deliv. Rev. 1998, 29:39-49.
16. Hussain A., Paulson J. Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies. Pharm. Res. 2004, 21:1127-1136.
17. Illum L. Nasal drug delivery-possibilities, problems and solutions. J. Control Release 2003, 87:187-198.
18. Jiang X.G., Cui J.B., Fang X.L., Wei Y., Xi N.Z. Toxicity of drugs on nasal mucocilia and the method of its evaluation. Acta Pharm. Sin. 1995, 30:848-853.
19. Kast C.E., Valenta C., Leopold M., Bernkop-Schnürch A. Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for clotrimazole. J. Control Release 2002, 81:347-354.
20. Lin H.X., Gebhardt M., Bian S.J., Kwon K.A., Shim C.K., Chung S.J., Kim D.D. Enhancing effect of surfactants on fexofenadine HCl transport across the human nasal epithelial cell monolayer. Int. J. Pharm. 2007, 330:23-31.
21. Liu J., Qiu L.Y., Gao J.Q., Jin Y. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 2006, 312:137-143.
22. Mao S., Shi Z., Bi D. Analgin nasal absorption. Chin. Pharm. J. 1997, 32:87-91.
23. Mao S., Shuai X., Unger F., Simona M., Bi D.Z., Kissel T. The depolymerization of chitosan: effects on physicochemical and biological properties. Int. J. Pharm. 2004, 281:45-54.
24. Mao S., Shuai X., Unger F., Wittmar M., Xie X., Kissel T. Synthesis, characterization and cytotoxicity of poly(ethylene glycol)-graft-trimethyl chitosan block copolymers. Biomaterials 2005, 26:6343-6356.
25. Mao S., Yang S., Bi D. Pharmacodynamics and potential toxicity of intranasally administrated dipyrone. Biol. Pharm. Bull. 2006, 29:1355-1359.
26. Maskarinec S.A., Hannig J., Lee R.C., Lee K.Y.C. Direct observation of poloxamer188 insertion into lipid monolayers. Biophys. J. 2002, 82:1453-1459.
27. Mei D., Mao S.R., Sun W., Wang Y.J., Kissel T. Effect of chitosan structure properties and molecular weight on the intranasal absorption of tetramethylpyrazine phosphate in rats. Eur. J. Pharm. Biopharm. 2008, 70:874-881.
28. Moghimi S.M., Hunter A.C. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol. 2000, 18:412-420.
29. Pimienta C., Chouinard F., Labib A., Lenaerts V. Effect of various poloxamer coatings on in vitro adhesion of isohexylcyanoacrylate nanospheres to rat ileal segments under liquid flow. Int. J. Pharm. 1992, 80:1-8.
30. Salzman R., Manson J.E., Griffing G.T., Kimmerle R., Ruderman N., McCall A., Stoltz E.J., Mullin C., Small S., Armstrong J., Melby J.C. Intranasal aerosolized insulin. N. Engl. J. Med. 1985, 312:1078-1084.
31. Sanico A.M., Atsuta S., Proud D., Togias A. Dose-dependent effects of capsaicin nasal challenge: in vivo evidence of human airway neurogenic inflammation. J. Allergy Clin. Immunol. 1997, 100:632-641.
32. Schipper N.G.M., Verhoef J., Romeijn S.G., Merkus F.W.H.M. Absorption enhancers in nasal insulin delivery and their influence on nasal ciliary functioning. J. Control Release 1992, 21:173-186.
33. Schipper N.G.M., Verhoef J.C., Romeijn S.G., Merkus F.W.H.M. Methylated β-cyclodextrins are able to improve the nasal absorption of salmon calcitonin. Calcifi. Tissue Int. 1995, 56:280-282.
34. Shao Y.Y., Zhao Y., Wu F.L., et al. Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies. Int. J. Pharm. 2004, 281:11-23.
35. Sinswat P., Tengamnuay P. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-β-cyclodextrins. Int. J. Pharm. 2003, 257:15-22.
36. Wearley L.L. Recent progress in protein and peptide delivery by noninvasive routes. Crit. Rev. Ther. Drug Carrier Syst. 1991, 8:331-394.
37. Zhao J.H., Fu J.H., Wang S.M., Su C.H., Shan Y., Kong S.J., Wang Y., Lu W.L., Zhang H., Zhang S., Li L., Zhang E.H., Wang L., Pei Q.L., Wang J.C., Zhang X., Zhang Q. A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. Int. J. Pharm. 2007, 337:88-101.